Table 2.

Rate of pseudoprogression in patients with melanoma or NSCLC

First author, year [reference]	Number of patients	Type of cancer	Treatment	Pseudoprogression (%)
Wolchock, 2009 [17]	227	Melanoma	Ipilimumab	9.7
Hodi, 2016 [26]	327	Melanoma	Pembrolizumab	7.0
Nishino, 2017 [24]	107	Melanoma	Pembrolizumab	5.0
Gettinger, 2015 [84]	129	NSCLC	Nivolumab	5.0
Nishino, 2017 [85]	160	NSCLC	Nivolumab or pembrolizumab	0.6
Katz, 2018 [86]	166	NSCLC	Anti-PD1 (nivolumab 80%)	2.0
Fujimoto, 2019 [27]	542	NSCLC	Nivolumab	3.0

PD-1 Programmed cell death protein 1, NSCLC Non-small cell lung cancer